cardiovascular disease to reduce metabolic risk. A multidisciplinary approach involving hepatologists and diabetologists alongside allied health professionals providing structured lifestyle advice is advocated. Objective evaluations of this approach are limited.

Methods We undertook a retrospective study to determine the impact of a large, tertiary centre, multidisciplinary metabolic hepatology clinic. Detailed health parameters and surrogate markers for liver and cardio-metabolic disease were evaluated and a health economic analysis was performed.

Results 165 patients with NAFLD without hepatic co-morbidity and excluding those undergoing bariatric surgery, and who attended ≥2 times between 2014–17, were followed from referral until latest review. Median follow-up was 13 months (2–34). At baseline, 29% had cirrhosis and 59% had T2DM. At follow-up, median liver stiffness, measured using transient elastography, decreased by 1.3 kPa (14%, p=0.0097) and was associated with significant improvement in alanine aminotransferase (ALT: −11 IU/L, 21%, p<0.0001). Median weight fell by 3.3 kg (3.4%, p=0.0005) as did total cholesterol (0.7 mmol/L; 14%, p=0.0023). Median HbA1c also fell (1.5 mmol/mol, 3.1%, p=0.0045). Reduction was most marked in those with poorly controlled T2DM (HbA1c>58 mmol/mol at baseline: 14 mmol/mol, 18%, p<0.0001). These improvements resulted in a 6.4% reduction in 10-year cardiovascular risk (QRISK3, age-sex-match, p=0.0085).

Preliminary economic analysis of our approach using the UKPDS Outcomes Model in patients with poorly controlled diabetes indicated improvement in quality adjusted life expectancy alongside a reduction in costs of complications if health improvements were maintained. Importantly, preliminary estimates appeared to be below the cost-per-QALY (quality adjusted life year) threshold of £20 000 for commissioning outcomes for these individuals. It is expected that this algorithm will be used by the HCC-UK/National Cancer Registration and Analysis Service partnership in forthcoming population-based studies of HCC outcomes in England.

PWE-076 IMPACT OF CIRRHOSIS SEVERITY ON SURVIVAL IN HEPATOCELLULAR CARCINOMA

Robert Driver*, David Chizhane, Rebecca Jones, Ian Rowe. Leeds Teaching Hospitals, Leeds, UK

10.1136/gutjnl-2018-BSGAbstracts.218

Introduction Treatment allocation and overall survival in hepatocellular carcinoma (HCC) is determined by both cancer characteristics and the severity of underlying liver disease. Treatments with the greatest chance of providing cure are often contraindicated by advanced cirrhosis. Routine healthcare data may be used to establish survival following different treatment modalities, but in the absence of biochemistry laboratory results, few data exist to determine cirrhosis stage at HCC presentation in population-based studies. We present the Results of a pilot study to determine liver disease severity using routinely collected diagnosis and treatment codes related to cirrhosis in hospital episodes at a regional hepatobiliary cancer centre in the UK.

Methods All patients registered within three local Leeds clinical commission groups (CCGs) with a new diagnosis of HCC over a two year period (January 2013 to December 2014) were identified. Using hospital episode codes related to varices and ascites, an algorithm was developed to determine cirrhosis severity as defined by the Baveno stage. Patients were stratified according to decomposition status: compensated cirrhosis by Baveno 1 and 2 and decompensated cirrhosis by Baveno 3 and 4. This staging was validated by comparison with clinical records. Data related to demographics, liver disease aetiology and treatment allocation were collected, along with laboratory data to compare with MELD and Child Pugh (CP) scores. Kaplan-Meier survival analysis was used to compare outcomes by liver disease severity.

Results Among 78 patients with a new diagnosis of HCC (median age 69 years, 61 (78%) male), 54 patients (69%) had evidence of cirrhosis at presentation. The most frequent underlying disease aetiologies were hepatitis C (26%) and alcohol-related liver disease (24%). Patients with compensated cirrhosis had a median survival of 22.9 months and those with decompensated cirrhosis it was 2.6 months (p=0.014). The decompensated group had a median CP score of 9 and MELD of 13, compared with a median CP score of 5 and MELD of 10 in the compensated group. The Baveno algorithm correctly determined the Baveno score in 53/54 (98%) patients with cirrhosis.

Conclusion Our Results demonstrate that the liver and cardio-metabolic health of patients with NAFLD managed through a multidisciplinary approach show significant improvements. Patients with poorly controlled T2DM had the greatest improvement in HbA1c of a magnitude known to reduce complications, which may potentially confer good benefit to patients in slowing NAFLD progression. Furthermore, our economic analysis suggests that the approach may be cost-effective.
inclusion criteria. Patients were included if they had an increased BMI (≥30 or ≥27.5 in high risk ethnicities) or waist circumference (>94 cm men or >80 cm men high risk ethnicities and >80 cm women) and low alcohol intake (<28 units/week males or <21 units/week females). AST/ALT ratio, Fibrosis-4 score (FIB-4) and NAFLD score were calculated for each patient. Those with an increased fibrosis score were reviewed in outpatients and had further investigations; non-invasive liver screen, liver ultrasound scan and liver elastography.

Results Out of the 82 included patients, 64 (78%) had at least one increased fibrosis score. Twenty-six patients with raised fibrosis score/s were reviewed in outpatient clinic and were offered further investigations. Of 15 patients who had an US scan 10 (66%) had fatty liver and the rest were normal. Twenty-one patients had liver elastography and 1 was found to have possible fibrosis with a fibrosis score of 8.1 kPa. Subsequent liver histology showed fibrosis, however it was thought to be drug induced.

Conclusions Informal feedback from the staff performing the NHS Health Check indicated that incorporating the liver screen was not burdensome. However, based on these results simple fibrosis markers are not a useful screening test for use in primary care, as the high false positive rate resulted in too many unnecessary referrals to secondary care to exclude fibrosis. It remains unclear how patients with liver fibrosis can be easily identified in primary care.

Conclusion

East Kent Trusts followed national guidelines in starting secondary LTP for SBP in 18% (10 out of possible 56) of cases and 0% of cases requiring primary LTP from April 2014 to April 2017. This low adherence rate may reflect lack of clinician awareness of guidelines for prescribing LTP for SBP in patients with ascites. There may also be a relation to local microbiology guidelines not following BSG or NICE guidelines on initiation of primary or secondary LTP for SBP. This study serves as a reminder to clinicians to carefully consider LTP in patients with ascites secondary to cirrhosis on each admission. We also recommend that trusts review local microbiology guidelines to ensure it adheres to national guidelines.

REFERENCES

PWE-079 DIAGNOSTIC UTILITY OF AUTOIMMUNE SEROLOGY PROFILING

1,2Debashis Haldar*, 1Tim Plant, 1Olivia Serevina, 1Kenneth Chung, 1Kashif Qamar, 1Bridget Gunson, 1Andrew Holt, 1,2Alex Richter, 1,2Gideon Hirsfield. 1Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK, 2University Hospitals Birmingham NHSFT, Birmingham, UK, 3Department of Clinical Immunology, University of Birmingham, Birmingham, UK, 4College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

Introduction Immunoserologic investigation is of clinical use in the discrimination of liver disease of autoimmune aetiology from alternate causes. We sought to investigate the diagnostic utility of immune serology in patients investigated for liver disease.

Methods We analysed the immunoprofile of patients investigated for liver disease at a tertiary centre between 2001 and 2017. We compared Results for patients clinically coded with a diagnosis of autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), or primary sclerosing cholangitis (PSC) against those without, amongst patients investigated by our liver services. Overlap features (o/f) were included if clinically documented.

Results We evaluated Results from 2874 patients. Patients with AIH (n=356; incl. o/f (19.3%)) were predominantly female (3:1; M:F), with a bimodal age distribution at presentation (18, 62 years). Antinuclear (ANA) and smooth muscle antibodies (SMA) were both sensitive (92.3%, 86.6% respectively) for a diagnosis of AIH, but poorly specific (23.6%, 27.2%). Amongst patients with TgAIH, 39 patients had antibodies to soluble liver antigen (SLA). Of these, 36 (92%) had concordance to Ro-52 antibodies. 2.3% of patients with TgAIH, defined by antibodies to liver-kidney microsome-1 (LKLM); of the 13 patients, 4 had SMA and 8 have ANA reactivity. Patients with PBC (n=527; incl. o/f (18.3%)) were primarily female (9:1; M:F), and in their 6th decade (mean=56 years). Anti-mitochondrial antibodies (AMA) testing was both sensitive (70.6%) and specific (91.2%). In patients who were AMA negative at testing, anti-glycoprotein 210 (gp210) (sens 40.7%, spec 95%) and anti-SP100 (sens 40.3%, spec 96.3%) proved useful diagnostic adjuncts. Patients with PSC (n=291; incl. o/f (10.1%)) were predominantly male (3